Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2006-12

AUTHORS

Vanna Chiarion-Sileni, Paola Del Bianco, Antonella Romanini, Michele Guida, Adriano Paccagnella, Maurizio Dalla Palma, Emanuele Naglieri, Ruggero Ridolfi, Barbara Silvestri, Maria Michiara, Gian Luca De Salvo

ABSTRACT

BACKGROUND: High-dose interferon alfa-2b (IFNalfa-2b), according to the ECOG 1684 schedule, is the only approved adjuvant treatment for stage III melanoma patients by the FDA and EMEA. However, the risk/benefit profile has been questioned limiting its world-wide use. In the late nineties, the Italian Melanoma Inter-group started a spontaneous randomized clinical trial (RCT) to verify if a more intense, but shorter than the ECOG 1684 regimen, could improve survival without increasing the toxicity profile. The safety analysis in the first 169 patients who completed the treatment is here described. METHODS: Stage III melanoma patients were randomized to receive IFNalfa-2b 20 MU/m2/d intravenously (IV) 5 days/week x 4 weeks, repeated for three times on weeks 9 to 12, 17 to 20, 25 to 28 (Dose-Dense/Dose-Intense, DD/DI, arm), or IFNalfa-2b 20 MU/m2/d IV 5 days/week x 4 weeks followed by 10 MU/m2 subcutaneously (SC) three times per week x 48 weeks (High Dose Interferon, HDI, arm). Toxicity was recorded and graded, according to the WHO criteria, as the worst grade that occurred during each cycle. RESULTS: The most common toxicities in both arms were flu-like and gastrointestinal symptoms, leukopenia, liver and neuro-psychiatric morbidities; with regard to severe toxicity, only leukopenia was statistically more frequent in DD/DI arm than in HDI arm (24% vs 9%) (p = 0.0074), yet, this did not cause an increase in the infection risk. Discontinuation of treatment, due to toxicity, was observed in 13 and 17% of the patients in the DD/DI and HDI arm, respectively. The median actual dose intensity delivered in the DD/DI arm (36.4 MU/m2/week) was statistically higher than that delivered in the HDI arm (30.7 MU/m2/week) (p = 0.003). CONCLUSION: Four cycles of intravenous high-dose IFNalfa-2b can be safely delivered with an increase in the median dose intensity. Efficacy results from this trial are eagerly awaited. More... »

PAGES

44

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/1471-2407-6-44

DOI

http://dx.doi.org/10.1186/1471-2407-6-44

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1039796167

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/16504154


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Chemotherapy, Adjuvant", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Schedule", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Infusions, Intravenous", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Interferon-alpha", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Italy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Melanoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Recombinant Proteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Skin Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tomography, X-Ray Computed", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Azienda Ospedaliera di Padova", 
          "id": "https://www.grid.ac/institutes/grid.411474.3", 
          "name": [
            "Department of Medical Oncology, University Hospital, Padua, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chiarion-Sileni", 
        "givenName": "Vanna", 
        "id": "sg:person.0707113743.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0707113743.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Istituto Oncologico Veneto", 
          "id": "https://www.grid.ac/institutes/grid.419546.b", 
          "name": [
            "Clinical Trials and Biostatistics Unit, Istituto Oncologico Veneto, Padua, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Del Bianco", 
        "givenName": "Paola", 
        "id": "sg:person.0707026774.05", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0707026774.05"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Azienda Ospedaliera Universitaria Pisana", 
          "id": "https://www.grid.ac/institutes/grid.144189.1", 
          "name": [
            "Medical Oncology Unit, S. Chiara Hospital, Pisa, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Romanini", 
        "givenName": "Antonella", 
        "id": "sg:person.0764656474.81", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0764656474.81"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Medical Oncology Unit, Ospedale Oncologico, Bari, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Guida", 
        "givenName": "Michele", 
        "id": "sg:person.01340562667.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01340562667.17"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Medical Oncology Unit, SS Giovanni e Paolo Hospital, Venezia, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Paccagnella", 
        "givenName": "Adriano", 
        "id": "sg:person.01213245211.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01213245211.15"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ospedale San Bortolo", 
          "id": "https://www.grid.ac/institutes/grid.416303.3", 
          "name": [
            "Medical Oncology Unit, S. Bortolo Hospital, Vicenza, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dalla Palma", 
        "givenName": "Maurizio", 
        "id": "sg:person.015335105625.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015335105625.43"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Medical Oncology Unit, Ospedale Oncologico, Bari, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Naglieri", 
        "givenName": "Emanuele", 
        "id": "sg:person.0646173240.64", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0646173240.64"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ospedale G.B. Morgagni - L.Pierantoni", 
          "id": "https://www.grid.ac/institutes/grid.415079.e", 
          "name": [
            "Oncology Dept, Pierantoni Hospital, Forl\u00ec, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ridolfi", 
        "givenName": "Ruggero", 
        "id": "sg:person.01050453536.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01050453536.03"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Medical Oncology Unit, General Hospital, Noale (Ve), Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Silvestri", 
        "givenName": "Barbara", 
        "id": "sg:person.01234137447.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01234137447.23"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Medical Oncology Unit, General Hospital, Parma, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Michiara", 
        "givenName": "Maria", 
        "id": "sg:person.0755721753.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0755721753.34"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Istituto Oncologico Veneto", 
          "id": "https://www.grid.ac/institutes/grid.419546.b", 
          "name": [
            "Clinical Trials and Biostatistics Unit, Istituto Oncologico Veneto, Padua, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "De Salvo", 
        "givenName": "Gian Luca", 
        "id": "sg:person.0605217455.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0605217455.41"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1200/jco.2005.00.075", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006229429"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1034/j.1600-0609.2001.00503.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007057244"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf02361253", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012030331", 
          "https://doi.org/10.1007/bf02361253"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf02361253", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012030331", 
          "https://doi.org/10.1007/bf02361253"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2004.10.907", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048989214"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074603206", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2000.18.12.2444", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074654627"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2001.19.5.1430", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074777251"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2001.19.9.2370", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074807640"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2001.19.16.3622", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074864906"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2001.19.16.3635", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074864907"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1075071647", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1075175285", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1990.8.12.1935", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1078512795"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.23.16_suppl.7517", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1079369743"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082394274", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082732106", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1996.14.1.7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1082858583"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1996.14.10.2666", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1082983619"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2006-12", 
    "datePublishedReg": "2006-12-01", 
    "description": "BACKGROUND: High-dose interferon alfa-2b (IFNalfa-2b), according to the ECOG 1684 schedule, is the only approved adjuvant treatment for stage III melanoma patients by the FDA and EMEA. However, the risk/benefit profile has been questioned limiting its world-wide use. In the late nineties, the Italian Melanoma Inter-group started a spontaneous randomized clinical trial (RCT) to verify if a more intense, but shorter than the ECOG 1684 regimen, could improve survival without increasing the toxicity profile. The safety analysis in the first 169 patients who completed the treatment is here described.\nMETHODS: Stage III melanoma patients were randomized to receive IFNalfa-2b 20 MU/m2/d intravenously (IV) 5 days/week x 4 weeks, repeated for three times on weeks 9 to 12, 17 to 20, 25 to 28 (Dose-Dense/Dose-Intense, DD/DI, arm), or IFNalfa-2b 20 MU/m2/d IV 5 days/week x 4 weeks followed by 10 MU/m2 subcutaneously (SC) three times per week x 48 weeks (High Dose Interferon, HDI, arm). Toxicity was recorded and graded, according to the WHO criteria, as the worst grade that occurred during each cycle.\nRESULTS: The most common toxicities in both arms were flu-like and gastrointestinal symptoms, leukopenia, liver and neuro-psychiatric morbidities; with regard to severe toxicity, only leukopenia was statistically more frequent in DD/DI arm than in HDI arm (24% vs 9%) (p = 0.0074), yet, this did not cause an increase in the infection risk. Discontinuation of treatment, due to toxicity, was observed in 13 and 17% of the patients in the DD/DI and HDI arm, respectively. The median actual dose intensity delivered in the DD/DI arm (36.4 MU/m2/week) was statistically higher than that delivered in the HDI arm (30.7 MU/m2/week) (p = 0.003).\nCONCLUSION: Four cycles of intravenous high-dose IFNalfa-2b can be safely delivered with an increase in the median dose intensity. Efficacy results from this trial are eagerly awaited.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/1471-2407-6-44", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1024632", 
        "issn": [
          "1471-2407"
        ], 
        "name": "BMC Cancer", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "6"
      }
    ], 
    "name": "Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI \u2013 Mel.A.) [ISRCTN75125874]", 
    "pagination": "44", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "bd9267b2b78ce085c046ac016f06da05b3ac3d39e8bc566551b27868ae84ba63"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "16504154"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "100967800"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/1471-2407-6-44"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1039796167"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/1471-2407-6-44", 
      "https://app.dimensions.ai/details/publication/pub.1039796167"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T23:32", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8693_00000551.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1186%2F1471-2407-6-44"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/1471-2407-6-44'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/1471-2407-6-44'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/1471-2407-6-44'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/1471-2407-6-44'


 

This table displays all metadata directly associated to this object as RDF triples.

266 TRIPLES      21 PREDICATES      61 URIs      35 LITERALS      23 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/1471-2407-6-44 schema:about N0e85c2c5f1044e76af37203aebf5c13b
2 N26342635197242d6bd491b31294ad0b5
3 N5215320460564ff7ad29a7d15d6ef507
4 N6bc7f7a27e8d4d6aa1d4d48fcd3fe5cf
5 N70ef431b91e845a385a83bc71363d32a
6 N79afa37343174922a29780d83f097389
7 N79f5bc18264644f8ae68e1ea237863f3
8 N845e84f1cd97412c8a4fdcd155d73ede
9 N85883ec1e2d04524a0346f4938e53caf
10 N86a120fb0d8f485283d0f25a11e7b243
11 Nc694295956ad4bab899be6c3ab28f8e4
12 Nd20e643d885945399b50738bb3504ab5
13 Nd2d7f952b269431ea8293eb44731860c
14 Ndd9c0d1965c5479690c36de541aa7a15
15 anzsrc-for:11
16 anzsrc-for:1112
17 schema:author N14e11c773923499daa96eb47930efa2e
18 schema:citation sg:pub.10.1007/bf02361253
19 https://app.dimensions.ai/details/publication/pub.1074603206
20 https://app.dimensions.ai/details/publication/pub.1075071647
21 https://app.dimensions.ai/details/publication/pub.1075175285
22 https://app.dimensions.ai/details/publication/pub.1082394274
23 https://app.dimensions.ai/details/publication/pub.1082732106
24 https://doi.org/10.1034/j.1600-0609.2001.00503.x
25 https://doi.org/10.1200/jco.1990.8.12.1935
26 https://doi.org/10.1200/jco.1996.14.1.7
27 https://doi.org/10.1200/jco.1996.14.10.2666
28 https://doi.org/10.1200/jco.2000.18.12.2444
29 https://doi.org/10.1200/jco.2001.19.16.3622
30 https://doi.org/10.1200/jco.2001.19.16.3635
31 https://doi.org/10.1200/jco.2001.19.5.1430
32 https://doi.org/10.1200/jco.2001.19.9.2370
33 https://doi.org/10.1200/jco.2004.10.907
34 https://doi.org/10.1200/jco.2005.00.075
35 https://doi.org/10.1200/jco.2005.23.16_suppl.7517
36 schema:datePublished 2006-12
37 schema:datePublishedReg 2006-12-01
38 schema:description BACKGROUND: High-dose interferon alfa-2b (IFNalfa-2b), according to the ECOG 1684 schedule, is the only approved adjuvant treatment for stage III melanoma patients by the FDA and EMEA. However, the risk/benefit profile has been questioned limiting its world-wide use. In the late nineties, the Italian Melanoma Inter-group started a spontaneous randomized clinical trial (RCT) to verify if a more intense, but shorter than the ECOG 1684 regimen, could improve survival without increasing the toxicity profile. The safety analysis in the first 169 patients who completed the treatment is here described. METHODS: Stage III melanoma patients were randomized to receive IFNalfa-2b 20 MU/m2/d intravenously (IV) 5 days/week x 4 weeks, repeated for three times on weeks 9 to 12, 17 to 20, 25 to 28 (Dose-Dense/Dose-Intense, DD/DI, arm), or IFNalfa-2b 20 MU/m2/d IV 5 days/week x 4 weeks followed by 10 MU/m2 subcutaneously (SC) three times per week x 48 weeks (High Dose Interferon, HDI, arm). Toxicity was recorded and graded, according to the WHO criteria, as the worst grade that occurred during each cycle. RESULTS: The most common toxicities in both arms were flu-like and gastrointestinal symptoms, leukopenia, liver and neuro-psychiatric morbidities; with regard to severe toxicity, only leukopenia was statistically more frequent in DD/DI arm than in HDI arm (24% vs 9%) (p = 0.0074), yet, this did not cause an increase in the infection risk. Discontinuation of treatment, due to toxicity, was observed in 13 and 17% of the patients in the DD/DI and HDI arm, respectively. The median actual dose intensity delivered in the DD/DI arm (36.4 MU/m2/week) was statistically higher than that delivered in the HDI arm (30.7 MU/m2/week) (p = 0.003). CONCLUSION: Four cycles of intravenous high-dose IFNalfa-2b can be safely delivered with an increase in the median dose intensity. Efficacy results from this trial are eagerly awaited.
39 schema:genre research_article
40 schema:inLanguage en
41 schema:isAccessibleForFree true
42 schema:isPartOf N217cf24a3ed340af9d5984a655ff88c0
43 N6275d6f8f9404f218b8504d0b6986bf2
44 sg:journal.1024632
45 schema:name Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI – Mel.A.) [ISRCTN75125874]
46 schema:pagination 44
47 schema:productId N4929760a25bd407190b4e47ddf9336b3
48 N59a2abc715d7464c8225017495b51e73
49 N619acec908bc416fbd70dc72fe4d4a38
50 N8419b2b6cb7249b68daaf57f82a8af1d
51 Nf1af2e87b2674c6e9c470b885b94681b
52 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039796167
53 https://doi.org/10.1186/1471-2407-6-44
54 schema:sdDatePublished 2019-04-10T23:32
55 schema:sdLicense https://scigraph.springernature.com/explorer/license/
56 schema:sdPublisher N842207bf7b514751945eb7d28f4cddba
57 schema:url http://link.springer.com/10.1186%2F1471-2407-6-44
58 sgo:license sg:explorer/license/
59 sgo:sdDataset articles
60 rdf:type schema:ScholarlyArticle
61 N0e85c2c5f1044e76af37203aebf5c13b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
62 schema:name Recombinant Proteins
63 rdf:type schema:DefinedTerm
64 N14e11c773923499daa96eb47930efa2e rdf:first sg:person.0707113743.39
65 rdf:rest N5329548724e74876b507a9ad2f1bff26
66 N217cf24a3ed340af9d5984a655ff88c0 schema:volumeNumber 6
67 rdf:type schema:PublicationVolume
68 N26342635197242d6bd491b31294ad0b5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
69 schema:name Chemotherapy, Adjuvant
70 rdf:type schema:DefinedTerm
71 N2abdeda9ef734ac0ad8edb593b6d93cc rdf:first sg:person.0755721753.34
72 rdf:rest N4a90a719c8b24ce581e1675d5fe12511
73 N3a00c98167434d0280b4293a07137c31 schema:name Medical Oncology Unit, SS Giovanni e Paolo Hospital, Venezia, Italy
74 rdf:type schema:Organization
75 N4929760a25bd407190b4e47ddf9336b3 schema:name doi
76 schema:value 10.1186/1471-2407-6-44
77 rdf:type schema:PropertyValue
78 N4a90a719c8b24ce581e1675d5fe12511 rdf:first sg:person.0605217455.41
79 rdf:rest rdf:nil
80 N4de25f15073c4e15bf79fd11ce9ad2d2 schema:name Medical Oncology Unit, Ospedale Oncologico, Bari, Italy
81 rdf:type schema:Organization
82 N5215320460564ff7ad29a7d15d6ef507 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
83 schema:name Skin Neoplasms
84 rdf:type schema:DefinedTerm
85 N5329548724e74876b507a9ad2f1bff26 rdf:first sg:person.0707026774.05
86 rdf:rest Naae1fff365554e85af100e976ef6ac45
87 N59a2abc715d7464c8225017495b51e73 schema:name readcube_id
88 schema:value bd9267b2b78ce085c046ac016f06da05b3ac3d39e8bc566551b27868ae84ba63
89 rdf:type schema:PropertyValue
90 N5f66004bd4c54d81b499ca70148578d9 rdf:first sg:person.01050453536.03
91 rdf:rest Ndde85fae0adf4afc8fd32540ede6fe8d
92 N619acec908bc416fbd70dc72fe4d4a38 schema:name nlm_unique_id
93 schema:value 100967800
94 rdf:type schema:PropertyValue
95 N6275d6f8f9404f218b8504d0b6986bf2 schema:issueNumber 1
96 rdf:type schema:PublicationIssue
97 N659860031b494c27827ab722cc3098ec schema:name Medical Oncology Unit, General Hospital, Parma, Italy
98 rdf:type schema:Organization
99 N6bc7f7a27e8d4d6aa1d4d48fcd3fe5cf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
100 schema:name Tomography, X-Ray Computed
101 rdf:type schema:DefinedTerm
102 N70ef431b91e845a385a83bc71363d32a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Middle Aged
104 rdf:type schema:DefinedTerm
105 N79afa37343174922a29780d83f097389 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
106 schema:name Antineoplastic Agents
107 rdf:type schema:DefinedTerm
108 N79f5bc18264644f8ae68e1ea237863f3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Female
110 rdf:type schema:DefinedTerm
111 N80ffd35ea59d41cfb8245db345e8907e schema:name Medical Oncology Unit, Ospedale Oncologico, Bari, Italy
112 rdf:type schema:Organization
113 N8419b2b6cb7249b68daaf57f82a8af1d schema:name dimensions_id
114 schema:value pub.1039796167
115 rdf:type schema:PropertyValue
116 N842207bf7b514751945eb7d28f4cddba schema:name Springer Nature - SN SciGraph project
117 rdf:type schema:Organization
118 N845e84f1cd97412c8a4fdcd155d73ede schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Italy
120 rdf:type schema:DefinedTerm
121 N85883ec1e2d04524a0346f4938e53caf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Humans
123 rdf:type schema:DefinedTerm
124 N86a120fb0d8f485283d0f25a11e7b243 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Interferon-alpha
126 rdf:type schema:DefinedTerm
127 N88d6cd7ea1e440c698d4ad4219b5a118 schema:name Medical Oncology Unit, General Hospital, Noale (Ve), Italy
128 rdf:type schema:Organization
129 N95f1e2f0e0f149009faa3f849efbb5bb rdf:first sg:person.015335105625.43
130 rdf:rest N986b68de99e0401f87c06da6d9cf05c6
131 N986b68de99e0401f87c06da6d9cf05c6 rdf:first sg:person.0646173240.64
132 rdf:rest N5f66004bd4c54d81b499ca70148578d9
133 Naae1fff365554e85af100e976ef6ac45 rdf:first sg:person.0764656474.81
134 rdf:rest Ne4f3f8e6558942ffa0b59b574721d50d
135 Nc694295956ad4bab899be6c3ab28f8e4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Drug Administration Schedule
137 rdf:type schema:DefinedTerm
138 Nd20e643d885945399b50738bb3504ab5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Infusions, Intravenous
140 rdf:type schema:DefinedTerm
141 Nd2d7f952b269431ea8293eb44731860c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Male
143 rdf:type schema:DefinedTerm
144 Ndd9c0d1965c5479690c36de541aa7a15 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Melanoma
146 rdf:type schema:DefinedTerm
147 Ndde85fae0adf4afc8fd32540ede6fe8d rdf:first sg:person.01234137447.23
148 rdf:rest N2abdeda9ef734ac0ad8edb593b6d93cc
149 Ne4f3f8e6558942ffa0b59b574721d50d rdf:first sg:person.01340562667.17
150 rdf:rest Neafe94268137419ea67abfce68691626
151 Neafe94268137419ea67abfce68691626 rdf:first sg:person.01213245211.15
152 rdf:rest N95f1e2f0e0f149009faa3f849efbb5bb
153 Nf1af2e87b2674c6e9c470b885b94681b schema:name pubmed_id
154 schema:value 16504154
155 rdf:type schema:PropertyValue
156 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
157 schema:name Medical and Health Sciences
158 rdf:type schema:DefinedTerm
159 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
160 schema:name Oncology and Carcinogenesis
161 rdf:type schema:DefinedTerm
162 sg:journal.1024632 schema:issn 1471-2407
163 schema:name BMC Cancer
164 rdf:type schema:Periodical
165 sg:person.01050453536.03 schema:affiliation https://www.grid.ac/institutes/grid.415079.e
166 schema:familyName Ridolfi
167 schema:givenName Ruggero
168 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01050453536.03
169 rdf:type schema:Person
170 sg:person.01213245211.15 schema:affiliation N3a00c98167434d0280b4293a07137c31
171 schema:familyName Paccagnella
172 schema:givenName Adriano
173 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01213245211.15
174 rdf:type schema:Person
175 sg:person.01234137447.23 schema:affiliation N88d6cd7ea1e440c698d4ad4219b5a118
176 schema:familyName Silvestri
177 schema:givenName Barbara
178 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01234137447.23
179 rdf:type schema:Person
180 sg:person.01340562667.17 schema:affiliation N4de25f15073c4e15bf79fd11ce9ad2d2
181 schema:familyName Guida
182 schema:givenName Michele
183 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01340562667.17
184 rdf:type schema:Person
185 sg:person.015335105625.43 schema:affiliation https://www.grid.ac/institutes/grid.416303.3
186 schema:familyName Dalla Palma
187 schema:givenName Maurizio
188 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015335105625.43
189 rdf:type schema:Person
190 sg:person.0605217455.41 schema:affiliation https://www.grid.ac/institutes/grid.419546.b
191 schema:familyName De Salvo
192 schema:givenName Gian Luca
193 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0605217455.41
194 rdf:type schema:Person
195 sg:person.0646173240.64 schema:affiliation N80ffd35ea59d41cfb8245db345e8907e
196 schema:familyName Naglieri
197 schema:givenName Emanuele
198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0646173240.64
199 rdf:type schema:Person
200 sg:person.0707026774.05 schema:affiliation https://www.grid.ac/institutes/grid.419546.b
201 schema:familyName Del Bianco
202 schema:givenName Paola
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0707026774.05
204 rdf:type schema:Person
205 sg:person.0707113743.39 schema:affiliation https://www.grid.ac/institutes/grid.411474.3
206 schema:familyName Chiarion-Sileni
207 schema:givenName Vanna
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0707113743.39
209 rdf:type schema:Person
210 sg:person.0755721753.34 schema:affiliation N659860031b494c27827ab722cc3098ec
211 schema:familyName Michiara
212 schema:givenName Maria
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0755721753.34
214 rdf:type schema:Person
215 sg:person.0764656474.81 schema:affiliation https://www.grid.ac/institutes/grid.144189.1
216 schema:familyName Romanini
217 schema:givenName Antonella
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0764656474.81
219 rdf:type schema:Person
220 sg:pub.10.1007/bf02361253 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012030331
221 https://doi.org/10.1007/bf02361253
222 rdf:type schema:CreativeWork
223 https://app.dimensions.ai/details/publication/pub.1074603206 schema:CreativeWork
224 https://app.dimensions.ai/details/publication/pub.1075071647 schema:CreativeWork
225 https://app.dimensions.ai/details/publication/pub.1075175285 schema:CreativeWork
226 https://app.dimensions.ai/details/publication/pub.1082394274 schema:CreativeWork
227 https://app.dimensions.ai/details/publication/pub.1082732106 schema:CreativeWork
228 https://doi.org/10.1034/j.1600-0609.2001.00503.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1007057244
229 rdf:type schema:CreativeWork
230 https://doi.org/10.1200/jco.1990.8.12.1935 schema:sameAs https://app.dimensions.ai/details/publication/pub.1078512795
231 rdf:type schema:CreativeWork
232 https://doi.org/10.1200/jco.1996.14.1.7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1082858583
233 rdf:type schema:CreativeWork
234 https://doi.org/10.1200/jco.1996.14.10.2666 schema:sameAs https://app.dimensions.ai/details/publication/pub.1082983619
235 rdf:type schema:CreativeWork
236 https://doi.org/10.1200/jco.2000.18.12.2444 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074654627
237 rdf:type schema:CreativeWork
238 https://doi.org/10.1200/jco.2001.19.16.3622 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074864906
239 rdf:type schema:CreativeWork
240 https://doi.org/10.1200/jco.2001.19.16.3635 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074864907
241 rdf:type schema:CreativeWork
242 https://doi.org/10.1200/jco.2001.19.5.1430 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074777251
243 rdf:type schema:CreativeWork
244 https://doi.org/10.1200/jco.2001.19.9.2370 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074807640
245 rdf:type schema:CreativeWork
246 https://doi.org/10.1200/jco.2004.10.907 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048989214
247 rdf:type schema:CreativeWork
248 https://doi.org/10.1200/jco.2005.00.075 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006229429
249 rdf:type schema:CreativeWork
250 https://doi.org/10.1200/jco.2005.23.16_suppl.7517 schema:sameAs https://app.dimensions.ai/details/publication/pub.1079369743
251 rdf:type schema:CreativeWork
252 https://www.grid.ac/institutes/grid.144189.1 schema:alternateName Azienda Ospedaliera Universitaria Pisana
253 schema:name Medical Oncology Unit, S. Chiara Hospital, Pisa, Italy
254 rdf:type schema:Organization
255 https://www.grid.ac/institutes/grid.411474.3 schema:alternateName Azienda Ospedaliera di Padova
256 schema:name Department of Medical Oncology, University Hospital, Padua, Italy
257 rdf:type schema:Organization
258 https://www.grid.ac/institutes/grid.415079.e schema:alternateName Ospedale G.B. Morgagni - L.Pierantoni
259 schema:name Oncology Dept, Pierantoni Hospital, Forlì, Italy
260 rdf:type schema:Organization
261 https://www.grid.ac/institutes/grid.416303.3 schema:alternateName Ospedale San Bortolo
262 schema:name Medical Oncology Unit, S. Bortolo Hospital, Vicenza, Italy
263 rdf:type schema:Organization
264 https://www.grid.ac/institutes/grid.419546.b schema:alternateName Istituto Oncologico Veneto
265 schema:name Clinical Trials and Biostatistics Unit, Istituto Oncologico Veneto, Padua, Italy
266 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...